Unveiling the Unprecedented: An Astonishing Rarity of Metoclopramide Hydrochloride-Triggered Nystagmus in a Pregnant Woman.

Metoclopramide hydrochloride is a widely used medication for the treatment of gastrointestinal disorders such as nausea, vomiting, and gastroparesis. However, it has been associated with extrapyramidal side effects (EPS) such as tardive dyskinesia, nystagmus, and other locomotive disorders on rare occasions. These reactions are commonly seen in children and females, particularly in young people. In this article, we report a rare case of a 15-week pregnant woman who was prescribed metoclopramide hydrochloride in view of nausea and vomiting, which was later diagnosed as vomiting in pregnancy not relieved with first-line medications, and has later developed drug-induced nystagmus, highlighting its unpredictable nature and shortcomings of management in the pregnant woman. This article will draw the attention of obstetricians and gynecologists to wisely prescribe metoclopramide hydrochloride for treating nausea and vomiting in pregnant women.

Effect of Amino Acid Infusion on Amniotic Fluid Index in Pregnancies Associated With Oligohydramnios and Fetal Growth Restriction.

Background Oligohydramnios and fetal growth restriction have been known for ages, with increased risk of disease and death during antenatal, neonatal, and adult life leading to operative interventions and perinatal mortality and morbidity. The amniotic fluid index varies with gestational age and is used to detect fetal well-being. Various oral and IV hydration and amino acid infusion therapies are studied to improve amniotic fluid index (AFI) and fetal weight. Objective To study the effect of intravenous amino acid infusion on AFI in pregnancies associated with oligohydramnios and fetal growth restriction (FGR). Material and methods A semi-experimental study done in Acharya Vinoba Bhave Rural Hospital (AVBRH), Sawangi Meghe, Wardha enrolled pregnant women in the in-patient department (IPD) unit of Obstetrics & Gynecology and divided them into two groups of 52 each, which met inclusion and exclusion criteria. Group A received IV amino acid infusion on an alternate day, whereas group B received IV hydration, and serial monitoring was done till delivery. Results The mean gestational age at admission was 32.73 ± 2.21 in the IV amino acid group and 32.25 ± 2.27 in the IV hydration group. In both groups, the mean AFI at admission was observed at 4.93±2.03 cm and 4.22 ± 2.00 cm, respectively. The mean AFI on the 14th day in the IV amino acid group was 7.52 ± 2.04, and in the IV hydration group, 5.89± 2.20 with a significant p-value of <0.0001.